The thesis

Medpace runs clinical trials for drugmakers chasing the GLP-1 and metabolic health boom. Revenue grew 8.5% year over year and net margin sits at 18.2%, solid execution for a contract research firm. Yet the stock trades at 36.2x earnings while our conviction score reads 31 of 100, a watchlist signal, and analysts consensus at hold. The tension is clear: the metabolicTheme narrative pays for acceleration the numbers do not yet show.

Why now

A risk-on rotation flagged by our macro model would add roughly five points to the score but remains inactive, so the setup is unconfirmed. Election-driven market swings have rotated capital sharply, and CRO names lag until that rotation activates.

What to watch

Watch quarterly revenue growth against the 8.5% baseline and any move in the risk-on rotation signal. Watch new contract bookings and gross margin versus 29.1% over the next one to three quarters for confirmation.

Key risks

Trial results and insurance coverage decisions for obesity drugs can swing demand for these names sharply in either direction. At 36.2x earnings on 8.5% growth, any slowdown in biotech trial spending compresses the multiple. A 29.1% gross margin leaves little cushion if pricing power erodes.

Theme exposure